Australia's most trusted
source of pharma news
Saturday, 27 July 2024
Posted 3 April 2024 AM
On average, the cost of listing a medicine on the PBS is set to rise by 5.6 per cent from July, a draft Cost Recovery Implementation Statement (CRIS), released by the Department of Health yesterday has revealed.
The CRIS sets out fees that will apply for the 2024-25 financial year - with all PBAC services facing a fee hike "ranging from 3.5 per cent to 7 per cent" compared to fees charged in the previous financial year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.